var title_f43_0_44032="Centruroides exilicauda 1";
var content_f43_0_44032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Centruroides exilicauda (sculpturatus) or bark scorpion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Banner Good Samaritan Medical Center, Department of Medical Toxicology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44032=[""].join("\n");
var outline_f43_0_44032=null;
var title_f43_0_44033="Groin abscess";
var content_f43_0_44033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Groin abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) A large abscess formed in the groin of the child, directly over the femoral vessels and nerve. B) A superficial incision produced an immediate return of pus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR. Selected Procedures. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44033=[""].join("\n");
var outline_f43_0_44033=null;
var title_f43_0_44034="Camphor and menthol: Drug information";
var content_f43_0_44034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Camphor and menthol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/62/38883?source=see_link\">",
"    see \"Camphor and menthol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15040925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Reports of Serious Burns Due to Topical Pain Relievers, FDA Issues Warning",
"     </span>",
"     <span class=\"collapsible-date\">",
"      September 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) is alerting the public that certain over-the-counter (OTC) topical pain relievers have been associated with rare cases of serious skin injuries (eg, first- to third-degree chemical burns) at the application site. In some cases, hospitalization has been required.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       OTC topical pain relievers are available as single- or combination-ingredient products that contain menthol, methyl salicylate, or capsaicin, and are marketed under brand names such as BenGay&reg;, Capzasin&reg;, Icy Hot&reg;, and Mentholatum&reg;. The formulations include creams, lotions, ointments, and patches.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Consumers who experience signs of skin injury (eg, pain, swelling, or blistering) following application of these products should discontinue their use and seek immediate medical attention. When recommending these pain relievers, healthcare providers should counsel patients about their appropriate use and the risk of burns.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm319353.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm319353.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Men-Phor [OTC];",
"     </li>",
"     <li>",
"      Mentholatum&reg; [OTC];",
"     </li>",
"     <li>",
"      Sarna&reg; [OTC];",
"     </li>",
"     <li>",
"      Soltice Quick-Rub&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dry skin: Topical: Apply as needed",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Soltice Quick-Rub&reg;: Camphor 5.1% and menthol 5.1% (40 g, 90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Men-Phor: Camphor 0.5% and menthol 0.5% (222 mL, 225 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sarna&reg;: Camphor 0.5% and menthol 0.5% (222 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mentholatum&reg;: Camphor 9% and menthol 1.3% (30 g, 90 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of dry, itching skin",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%: Dermatologic: Burning sensation, especially on broken skin",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7731745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; Pediatrics: The American Academy of Pediatrics suggests that camphor be avoided in pediatric patients because of its lack of efficacy and the well-documented toxicity that may occur with use (AAP, 1994). Although toxicity most often results from oral ingestion of topical or inhalation products, combined dermal and inhalation exposure has resulted in toxicity (Love, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14276554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following exposure to large concentrations (eg, oral ingestion observed with poisonings), camphor crosses the placenta and is toxic to the fetus (Rabl, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Ortho-Nesic External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2-3.5% (180 mL): $179.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (DermaSarra Anti-Itch External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-0.5% (222 mL): $7.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Men-Phor External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-0.5% (222 mL): $4.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Sarna External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-0.5% (222 mL): $7.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Tiger Balm Regular Strength External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     11-8% (18 g): $4.32",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Camphor Revisited: Focus on Toxicity,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 94(1):127-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/0/44034/abstract-text/8008522/pubmed\" id=\"8008522\" target=\"_blank\">",
"        8008522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Love JN, Sammon M, and Smereck J, &ldquo;Are One Or Two Dangerous? Camphor Exposure In Toddlers,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 2004, 27(1):49-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/0/44034/abstract-text/15219304/pubmed\" id=\"15219304\" target=\"_blank\">",
"        15219304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabl W, Katzgraber F, and Steinlechner M, \"Camphor Ingestion for Abortion (Case Report),\"",
"      <i>",
"       Forensic Sci Int",
"      </i>",
"      , 1997, 89(1-2):137-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/0/44034/abstract-text/9306672/pubmed\" id=\"9306672\" target=\"_blank\">",
"        9306672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8995 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44034=[""].join("\n");
var outline_f43_0_44034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15040925\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144864\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144871\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144865\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144866\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144860\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144851\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144861\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144869\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7731745\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298947\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218827\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144857\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14276554\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323038\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8995|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/62/38883?source=related_link\">",
"      Camphor and menthol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_0_44035="Dilated cardiomyopathy long axis echocardiogram";
var content_f43_0_44035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/75021/laxdilcm_conv.mp4?title=Dilated+cardiomyopathy+long+axis+echocardiogram\" style=\"width:312px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dilated cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parasternal long axis view from a 2-D echocardiogram shows a markedly dilated and hypokinetic left ventricle. The left atrium is also enlarged and there is reduced excursion of the mitral and aortic valves suggesting a reduced stroke volume.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44035=[""].join("\n");
var outline_f43_0_44035=null;
var title_f43_0_44036="Glycopyrrolate (glycopyrronium): Patient drug information";
var content_f43_0_44036=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Glycopyrrolate (glycopyrronium): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=see_link\">",
"     see \"Glycopyrrolate (glycopyrronium): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/4/43078?source=see_link\">",
"     see \"Glycopyrrolate (glycopyrronium): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cuvposa&trade;;",
"     </li>",
"     <li>",
"      Robinul&reg;;",
"     </li>",
"     <li>",
"      Robinul&reg; Forte",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2969522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Glycopyrrolate Injection, USP;",
"     </li>",
"     <li>",
"      Seebri&reg; Breezhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12784388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691855",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat GI (gastrointestinal) ulcers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691234",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In surgery, it is used to lower secretions such as saliva.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702211",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glycopyrrolate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems, a fast heartbeat, glaucoma, bowel block, myasthenia gravis, slow-moving GI (gastrointestinal) tract, ulcerative colitis, or trouble passing urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12516 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44036=[""].join("\n");
var outline_f43_0_44036=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176915\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2969522\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12784388\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012197\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012196\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012201\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012202\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012204\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012199\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012200\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012205\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012206\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/20/11591?source=related_link\">",
"      Glycopyrrolate (glycopyrronium): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/4/43078?source=related_link\">",
"      Glycopyrrolate (glycopyrronium): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_0_44037="Sodium picosulfate, magnesium oxide, and citric acid: Drug information";
var content_f43_0_44037=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium picosulfate, magnesium oxide, and citric acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14965743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prepopik&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14961940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oral Purgative;",
"     </li>",
"     <li>",
"      Pico-Salax&reg;;",
"     </li>",
"     <li>",
"      Picodan;",
"     </li>",
"     <li>",
"      Picoflo;",
"     </li>",
"     <li>",
"      Purg-Odan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14633323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Laxative, Osmotic;",
"     </li>",
"     <li>",
"      Laxative, Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14962161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Bowel cleansing:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prepopik&trade;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Split-dose regimen (preferred):",
"     </i>",
"     150 mL (5 oz) the evening before the colonoscopy (5 PM-9 PM), followed by a second 150 mL (5 oz) dose ~5 hours before the colonoscopy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Day-before regimen (alternative):",
"     </i>",
"     150 mL (5 oz) in the early evening before the colonoscopy (4 PM-6 PM), followed by a second 150 mL (5 oz) dose 6 hours later (10 PM-12 AM) the night before the colonoscopy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Purg-Odan&trade; (Canadian availability): One sachet (mixed and dissolved in water) in the morning (8 AM) the day prior to the procedure followed by a second dose of one sachet in the afternoon (2 PM-4 PM) on the day prior to the procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pico-Salax&reg; (Canadian availability):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Early colonoscopy (before 12 PM): One sachet (mixed and dissolved in water) in the evening (5 PM) the day prior to the procedure, followed by a second dose of one sachet 5 hours later (10 PM) the night before the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Late colonoscopy (after 12 PM): One sachet (mixed and dissolved in water) in the late evening (7 PM) the day prior to the procedure, followed by a second dose of one sachet in the morning (6 AM) on the day of the procedure",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14962160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Bowel cleansing:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Purg-Odan&trade; (Canadian availability): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-5 years: One-fourth (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     ) of one sachet (mixed and dissolved in water) in the morning (8 AM) the day prior to the procedure, followed by a second dose of one-fourth (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     ) of one sachet in the afternoon (2 PM-4 PM) on the day prior to the procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-12 years: One-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) of one sachet (mixed and dissolved in water) in the morning (8 AM) the day prior to the procedure, followed by a second dose of one-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) of one sachet in the afternoon (2 PM-4 PM) on the day prior to the procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pico-Salax&reg; (Canadian availability): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-5 years: One-fourth (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     ) of one sachet (mixed and dissolved in water) in the evening (6 PM) the day prior to the procedure, followed by a second dose of one-fourth (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     ) of one sachet in the morning (8 AM) on the day of the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-12 years: One-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) of one sachet (mixed and dissolved in water) in the evening (6 PM) the day prior to the procedure, followed by a second dose of one-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) of one sachet in the morning (8 AM) on the day of the procedure",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14962162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14962168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral [kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prepopik&trade;: Sodium picosulfate 10 mg, magnesium oxide 3.5 g, and citric acid 12 g per packet (2s) [orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F14962169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral [kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pico-Salax&reg;: Sodium picosulphate 10 mg, magnesium oxide 3.5 g, and citric acid 12 g per sachet (1s, 2s) [orange or cranberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Purg-Odan&trade;: Sodium picosulphate 10 mg, magnesium oxide 3.5 g, and citric acid 12 g per sachet (1s, 2s) [orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14961941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F14641979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM312633.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM312633.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14962163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prepopik&trade;: Following the first dose, administer five 8-ounce clear liquid drinks (eg, water, clear broth, apple juice, white cranberry juice, white grape juice, ginger ale, plain gelatin [not purple or red], frozen juice bars [not purple or red]) within 5 hours. Following the second dose, administer three 8-ounce clear liquid drinks within 5 hours of administration. Clear liquids may be consumed up until 2 hours prior to the colonoscopy. In patients who develop bloating, distension, or abdominal pain, temporarily discontinue administration or increase the dosing interval until symptoms improve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Purg-Odan&trade; (Canadian availability): Drink ~250 mL (8 oz) of clear liquids every hour while the effects of the bowel preparation regimen are apparent. Clear liquids may be consumed up until 2 hours prior to the procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pico-Salax&reg; (Canadian availability):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     At least 3 days prior to the procedure: Avoid eating seeds, nuts, fresh fruits and vegetables, and multigrain bread.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Day prior to the procedure: Consume clear liquids only (eg, water, clear power drinks, apple juice, white [not red] cranberry juice, white [not purple] grape juice, ginger ale, broth, tea [without milk, cream, or soy]), and no solid food. Patients with diabetes may drink a fiber-free supplement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Following each dose: Adults should drink 1.5-2 L of clear fluids up until 2 hours prior to the procedure; children should drink one 8-ounce drink every hour while awake and up until 2 hours prior to the procedure.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14633324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bowel cleansing prior to colonoscopy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional uses (not in U.S. labeling): Bowel cleansing prior to x-ray examination, endoscopy, or surgery",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14961960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypermagnesemia (9% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: GFR decreased (&le;48 hours after colonoscopy: 10% to 29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (5% to 7%), hypochloremia (1% to 4%), hyponatremia (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (3%), vomiting (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Serum creatinine increased (&lt;1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Aphthoid ileal ulcers, hypersensitivity, ischemic colitis, seizure",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14961946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium picosulfate, magnesium oxide, anhydrous citric acid, or any component of the formulation; GI obstruction or ileus; bowel perforation; gastric retention; toxic colitis; toxic megacolon; severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Congestive heart failure; GI ulceration; nausea; vomiting; acute surgical abdominal conditions (eg, acute appendicitis)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14961947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Arrhythmias: Serious arrhythmias have occurred rarely with the use of ionic osmotic laxative products; use caution in patients at increased risk for arrhythmias (eg, recent MI, unstable angina, cardiomyopathy, history of prolonged QT, HF, uncontrolled arrhythmias); consider baseline and post-colonoscopy ECGs in patients at increased risk for arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fluid and electrolyte abnormalities: May cause fluid and electrolyte disturbances, particularly in patients at increased risk (eg, renal impairment, concomitant medications that alter electrolyte balance). Any pre-existing electrolyte abnormalities should be corrected prior to use and patients should be adequately hydrated before, during, and after use. Consider evaluating for and treating post-colonoscopy electrolyte abnormalities in patients who develop significant vomiting, dehydration, or orthostatic hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; GI effects: Osmotic laxatives may produce colonic mucosal aphthous ulcerations, including cases of ischemic colitis. Use caution when interpreting colonoscopy results in patients with inflammatory bowel disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizures: Seizures associated with electrolyte abnormalities (eg, hyponatremia, hypokalemia) and low serum osmolality have occurred; use with caution in patients with underlying electrolyte disturbances and in patients at increased risk for seizures (eg, concomitant medications that lower seizure threshold, withdrawal from alcohol or benzodiazepines).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Impaired gag reflex: Observe unconscious or semiconscious patients with impaired gag reflex or those who are otherwise prone to regurgitation or aspiration during administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment and/or in patients taking medications that may adversely affect renal function (eg, diuretics, NSAIDs, ACE inhibitors); adequate hydration is particularly important in these patients. Patients with impaired renal function who develop severe vomiting should be closely monitored including measurement of electrolytes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with severe ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concomitant drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antibiotics: Sodium picosulfate requires the presence of colonic bacteria for the conversion to the active metabolite; prior or concomitant administration of antibiotics may reduce the efficacy of sodium picosulfate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Oral medications: Oral medications administered &le;1 hour prior to the start of the bowel preparation regimen may not be absorbed. Chlorpromazine, digoxin, fluoroquinolones, iron, penicillamine, and tetracycline should be administered at least 2 hours before and 6 hours after administration of magnesium oxide to avoid chelation with magnesium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Evaluate patients with symptoms of bowel obstruction/perforation (nausea, vomiting, abdominal pain or distension) prior to use. Each packet must be diluted with water prior to use; inadvertent administration of undiluted solution may increase the risk of nausea, vomiting, and fluid/electrolyte abnormalities.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14878080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14878078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antibiotics: May diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14961942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14961943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies using doses similar to a human dose.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14961944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14961945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lactating women (n=8) were administered sodium picosulfate 10 mg as an oral solution once daily for 8 days. The active metabolite, BPHM, was detected in plasma and urine, but below the limit of detection in breast milk (&lt;1 ng/mL) (Friedrich, 2011). Also refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Prepopik Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-3.5-12 mg-gm-gm (2): $89.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14962166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes and renal function tests (baseline and post-colonoscopy) in patients with or at risk for renal impairment or seizure, and in patients who have a history of electrolyte abnormality; consider ECG (baseline and post-colonoscopy) in patients at risk for prolonged QT or arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14962061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium picosulfate, a prodrug, is hydrolyzed by colonic bacteria to an active metabolite which stimulates colonic peristalsis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium oxide and citric acid react to create magnesium citrate which induces catharsis by the osmotic effects of the unabsorbed ions in the GI tract.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14962063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Magnesium cation: &ge;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Sodium picosulfate: Hydrolyzed by colonic bacteria to the active compound bis-(",
"     <i>",
"      p",
"     </i>",
"     -hydroxy-phenyl)-pyridyl-2-methane (BHPM)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Sodium picosulfate: ~7.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Sodium picosulfate: ~7 hours; Magnesium: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Friedrich C, Richter E, Trommeshauser D, et al, &ldquo;Absence of Excretion of the Active Moiety of Bisacodyl and Sodium Picosulfate into Human Breast Milk: An Open-Label, Parallel-Group, Multiple-Dose Study in Healthy Lactating Women,&rdquo;",
"      <i>",
"       Drug Metab Pharmacokinet",
"      </i>",
"      , 2011, 26(5):458-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/0/44037/abstract-text/21697613/pubmed\" id=\"21697613\" target=\"_blank\">",
"        21697613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoy S, Scott L, and Wagstaff A, &ldquo;Sodium Picosulfate/Magnesium Citrate: A Review of Its Use as a Colorectal Cleanser,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2009, 69(1):123-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/0/44037/abstract-text/19192941/pubmed\" id=\"19192941\" target=\"_blank\">",
"        19192941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85869 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-0E8DCFA2F5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44037=[""].join("\n");
var outline_f43_0_44037=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965743\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961940\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14633323\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14962161\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14962160\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14962162\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14962168\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14962169\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961941\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14641979\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14962163\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14633324\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961960\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961946\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961947\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14878080\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14878078\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961942\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961943\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961944\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14961945\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570443\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14962166\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14962061\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14962063\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/85869\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/85869|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_0_44038="Topical salicylic acid: Pediatric drug information";
var content_f43_0_44038=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topical salicylic acid: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/23/30072?source=see_link\">",
"    see \"Topical salicylic acid: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/17/16663?source=see_link\">",
"    see \"Topical salicylic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aliclen&trade;;",
"     </li>",
"     <li>",
"      Beta Sal&reg; [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; Advantage&reg; Acne Cleanser [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; Advantage&reg; Acne Spot Treatment [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; Advantage&reg; Invisible Acne Patch [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; Advantage&reg; Oil-Free Acne [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; Blackhead Clearing Daily Cleansing [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; Blackhead Clearing Scrub [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; Deep Cleaning [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; Dual Action Moisturizer [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; Invisible Blemish Treatment [OTC];",
"     </li>",
"     <li>",
"      Compound W&reg; One Step Invisible Strip [OTC];",
"     </li>",
"     <li>",
"      Compound W&reg; One Step Wart Remover for Feet [OTC];",
"     </li>",
"     <li>",
"      Compound W&reg; One-Step Wart Remover for Kids [OTC];",
"     </li>",
"     <li>",
"      Compound W&reg; One-Step Wart Remover [OTC];",
"     </li>",
"     <li>",
"      Compound W&reg; [OTC];",
"     </li>",
"     <li>",
"      Curad&reg; Mediplast&reg; [OTC];",
"     </li>",
"     <li>",
"      Denorex&reg; Extra Strength Protection 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Denorex&reg; Extra Strength Protection [OTC];",
"     </li>",
"     <li>",
"      Dermarest&reg; Psoriasis Medicated Moisturizer [OTC];",
"     </li>",
"     <li>",
"      Dermarest&reg; Psoriasis Medicated Scalp Treatment [OTC];",
"     </li>",
"     <li>",
"      Dermarest&reg; Psoriasis Medicated Shampoo/Conditioner [OTC];",
"     </li>",
"     <li>",
"      Dermarest&reg; Psoriasis Medicated Skin Treatment [OTC];",
"     </li>",
"     <li>",
"      Dermarest&reg; Psoriasis Overnight Treatment [OTC];",
"     </li>",
"     <li>",
"      DHS&trade; Sal [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Callus Removers [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Clear Away&reg; One Step Wart Remover [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Clear Away&reg; Plantar Wart Remover For Feet [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Clear Away&reg; Wart Remover Fast-Acting [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Clear Away&reg; Wart Remover Invisible Strips [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Clear Away&reg; Wart Remover [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Corn Removers [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Corn/Callus Remover [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Extra Thick Corn Removers [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Extra-Thick Callus Removers [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; For Her Corn Removers [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; OneStep Callus Removers [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; OneStep Corn Removers [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Small Corn Removers [OTC];",
"     </li>",
"     <li>",
"      Dr. Scholl's&reg; Ultra-Thin Corn Removers [OTC];",
"     </li>",
"     <li>",
"      DuoFilm&reg; [OTC];",
"     </li>",
"     <li>",
"      Freezone&reg; [OTC];",
"     </li>",
"     <li>",
"      Fung-O&reg; [OTC];",
"     </li>",
"     <li>",
"      Gets-It&reg; [OTC];",
"     </li>",
"     <li>",
"      Gordofilm [OTC];",
"     </li>",
"     <li>",
"      Hydrisalic&reg; [OTC];",
"     </li>",
"     <li>",
"      Ionil Plus&reg; [OTC];",
"     </li>",
"     <li>",
"      Ionil&reg; [OTC];",
"     </li>",
"     <li>",
"      Keralyt&reg;;",
"     </li>",
"     <li>",
"      Keralyt&reg; [OTC];",
"     </li>",
"     <li>",
"      LupiCare&reg; Dandruff [OTC];",
"     </li>",
"     <li>",
"      LupiCare&reg; Psoriasis [OTC];",
"     </li>",
"     <li>",
"      MG217&reg; Sal-Acid [OTC];",
"     </li>",
"     <li>",
"      Mosco&reg; Callus &amp; Corn Remover [OTC];",
"     </li>",
"     <li>",
"      Mosco&reg; One Step Corn Remover [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Acne Stress Control [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Advanced Solutions&trade; [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Blackhead Eliminating&trade; 2-in-1 Foaming Pads [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Blackhead Eliminating&trade; Daily Scrub [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Blackhead Eliminating&trade; [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Body Clear&reg; [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Clear Pore&trade; Oil-Controlling Astringent [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Maximum Strength T/Sal&reg; [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Oil-Free Acne Stress Control [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Oil-Free Acne Wash 60 Second Mask Scrub [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Oil-Free Acne Wash Cream Cleanser [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Oil-Free Acne Wash Foam Cleanser [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Oil-Free Acne Wash [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Oil-Free Acne [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Oil-Free Anti-Acne [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Rapid Clear&reg; Acne Defense [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Rapid Clear&reg; Acne Eliminating [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; Rapid Clear&reg; [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Body Wash [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Chill Factor&reg; [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Daily Cleansing [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Daily [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Face Wash [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Maximum Daily Cleansing [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Maximum [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Post-Shave [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Spot Treatment [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; [OTC];",
"     </li>",
"     <li>",
"      P&amp;S&reg; [OTC];",
"     </li>",
"     <li>",
"      Palmer's&reg; Skin Success Acne Cleanser [OTC];",
"     </li>",
"     <li>",
"      Sal-Plant&reg; [OTC];",
"     </li>",
"     <li>",
"      Salactic&reg; [OTC];",
"     </li>",
"     <li>",
"      Salex&reg;;",
"     </li>",
"     <li>",
"      Salvax;",
"     </li>",
"     <li>",
"      Scalpicin&reg; Anti-Itch [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Deep Cleaning Micro-Bead Scrub [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Naturals Island Breeze [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Naturals Itchy Dry Scalp [OTC];",
"     </li>",
"     <li>",
"      Stridex&reg; Essential Care&reg; [OTC];",
"     </li>",
"     <li>",
"      Stridex&reg; Facewipes To Go&reg; [OTC];",
"     </li>",
"     <li>",
"      Stridex&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Stridex&reg; Sensitive Skin [OTC];",
"     </li>",
"     <li>",
"      Thera-Sal [OTC] [DSC];",
"     </li>",
"     <li>",
"      Tinamed&reg; Corn and Callus Remover [OTC];",
"     </li>",
"     <li>",
"      Tinamed&reg; Wart Remover [OTC];",
"     </li>",
"     <li>",
"      Trans-Ver-Sal&reg; [OTC];",
"     </li>",
"     <li>",
"      Virasal&reg;;",
"     </li>",
"     <li>",
"      Wart-Off&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Zapzyt&reg; Acne Wash [OTC];",
"     </li>",
"     <li>",
"      Zapzyt&reg; Pore Treatment [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Duofilm&reg;;",
"     </li>",
"     <li>",
"      Duoforte&reg; 27;",
"     </li>",
"     <li>",
"      Occlusal&trade;-HP;",
"     </li>",
"     <li>",
"      Sebcur&reg;;",
"     </li>",
"     <li>",
"      Soluver&reg;;",
"     </li>",
"     <li>",
"      Soluver&reg; Plus;",
"     </li>",
"     <li>",
"      Trans-Plantar&reg;;",
"     </li>",
"     <li>",
"      Trans-Ver-Sal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Keratolytic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/23/30072?source=see_link\">",
"      see \"Topical salicylic acid: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 years and Adults: Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Foam: Apply to the affected area twice daily. Rub into skin until completely absorbed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, cream, gel: Apply a thin layer to the affected area once or twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Initial: Use daily or every other day; apply to wet hair and massage vigorously into the scalp; rinse hair thoroughly after shampooing; 1-2 treatments/week will usually maintain control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution: Apply a thin layer directly to wart using brush applicator once daily as directed for 1 week or until the wart is removed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical: 6% (70 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Salvax: 6% (70 g, 200 g) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bar, topical [soap]: 2% (113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg;: 0.5% (119 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cloth, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Oil-Free Acne Wash: 2% (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 6% (400 g, 480 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; Advantage&reg; Acne Cleanser: 2% (148 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; Advantage&reg; Acne Spot Treatment: 2% (22 g) [contains benzalkonium chloride, ethanol 14%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; Blackhead Clearing Scrub: 2% (141 g, 226 g) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; Dual Action Moisturizer: 0.5% (120 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LupiCare&reg; Psoriasis: 2% (227 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Acne Stress Control: 2% (125 g) [with microbeads]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Oil-Free Acne: 2% (125 mL) [contains ethanol, tartrazine; with microbeads]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Oil-Free Acne Wash Cream Cleanser: 2% (200 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Oil-Free Anti-Acne: 0.5% (50 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Salex&reg;: 6% (454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical [wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Oil-Free Acne Stress Control: 2% (172 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 6% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; Advantage&reg; Invisible Acne Patch: 2% (1.9 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; Invisible Blemish Treatment: 2% (22 mL) [contains ethanol 28%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compound W&reg;: 17.6% (7 g) [contains ethanol 67.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermarest&reg; Psoriasis Medicated Scalp Treatment: 3% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermarest&reg; Psoriasis Medicated Skin Treatment: 3% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermarest&reg; Psoriasis Overnight Treatment: 3% (56.7 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrisalic&reg;: 6% (28 g) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Keralyt&reg;: 3% (30 g); 6% (40 g, 100 g) [contains ethanol 21%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Oil-Free Acne Wash: 2% (177 mL, 296 mL) [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Rapid Clear&reg; Acne Eliminating: 2% (15 mL) [contains ethanol 38%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg;: 2% (355 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Body Wash: 2% (355 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Body Wash: 2% (355 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Chill Factor&reg;: 2% (142 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Face Wash: 2% (177 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Maximum: 2% (142 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Spot Treatment: 1% (14.7 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sal-Plant&reg;: 17% (14 g) [contains isopropyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zapzyt&reg; Acne Wash: 2% (188.5 g) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zapzyt&reg; Pore Treatment: 2% (22 mL) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical [peel]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Advanced Solutions&trade;: 2% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; Advantage&reg; Oil-Free Acne: 0.5% (120 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; Deep Cleaning: 2% (240 mL) [contains benzoic acid, ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compound W&reg;: 17.6% (9 mL) [contains ethanol 21.2%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Clear Away&reg; Wart Remover Fast-Acting: 17% (9.8 mL) [contains ethanol 18% w/w; includes 20 cover-up discs]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Corn/Callus Remover: 12.6% (9.8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Corn/Callus Remover: 12.6% (9.8 mL) [contains ethanol 18% w/w]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DuoFilm&reg;: 17% (9.8 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Freezone&reg;: 17.6% (9.3 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fung-O&reg;: 17% (15 mL) [contains ethanol 2%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gets-It&reg;: 13.9% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gordofilm: 16.7% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mosco&reg; Callus &amp; Corn Remover: 17.6% (9 mL) [contains ethanol 27%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Blackhead Eliminating&trade; Daily Scrub: 2% (125 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Clear Pore&trade; Oil-Controlling Astringent: 2% (236 mL) [contains ethanol 45%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Oil-Free Acne Stress Control: 2% (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Palmer's&reg; Skin Success Acne Cleanser: 0.5% (240 mL) [contains aloe, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Salactic&reg;: 17% (15 mL) [contains isopropyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scalpicin&reg; Anti-Itch: 3% (44 mL, 74 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinamed&reg; Corn and Callus Remover: 17% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinamed&reg; Wart Remover: 17% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Virasal&reg;: 27.5% (10 mL) [contains isopropyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wart-Off&reg; Maximum Strength: 17.5% (14.8 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [body scrub with microbeads]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Body Clear&reg;: 2% (250 mL) [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [body wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Body Clear&reg;: 2% (250 mL) [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [foam]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Oil-Free Acne Wash Foam Cleanser: 2% (150 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [foam/wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Oil-Free Acne Stress Control: 0.5% (177 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [mask/wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Oil-Free Acne Wash 60 Second Mask Scrub: 1% (170 g) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 6% (414 mL); 6% (400 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermarest&reg; Psoriasis Medicated Moisturizer: 2% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Rapid Clear&reg; Acne Defense: 2% (50 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Post-Shave: 0.5% (50 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Salex&reg;: 6% (237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MG217&reg; Sal-Acid: 3% (57 g) [contains vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pad, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; Blackhead Clearing Daily Cleansing: 1% (70s) [contains ethanol 39%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Curad&reg; Mediplast&reg;: 40% (25s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Blackhead Eliminating&trade;: 0.5% (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Blackhead Eliminating&trade; 2-in-1 Foaming Pads: 0.5% (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Rapid Clear&reg;: 2% (60s) [contains benzalkonium chloride, ethanol 35%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Chill Factor&reg;: 2% (90s) [contains ethanol 46% v/v]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Daily: 0.2% (90s) [contains ethanol 46% v/v]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Daily Cleansing: 0.5% (90s) [contains ethanol 34% v/v]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Maximum Daily Cleansing: 2% (55s, 90s) [contains ethanol 46% v/v]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stridex&reg; Essential Care&reg;: 1% (55s) [ethanol free; contains vitamin A, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stridex&reg; Facewipes To Go&reg;: 0.5% (32s) [contains aloe, ethanol 28%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stridex&reg; Maximum Strength: 2% (55s, 90s) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stridex&reg; Sensitive Skin: 0.5% (55s, 90s) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compound W&reg; One Step Invisible Strip: 14% (14s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compound W&reg; One Step Wart Remover for Feet: 40% (20s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compound W&reg; One-Step Wart Remover: 40% (14s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compound W&reg; One-Step Wart Remover for Kids: 40% (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Callus Removers: 40% (4s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Callus Removers: 40% (4s) [includes 6 cushions]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Clear Away&reg; One Step Wart Remover: 40% (14s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Clear Away&reg; Plantar Wart Remover For Feet: 40% (24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Clear Away&reg; Wart Remover: 40% (18s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Clear Away&reg; Wart Remover Invisible Strips: 40% (18s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Corn Removers: 40% (9s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Corn Removers: 40% (9s) [includes 9 cushions]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Extra Thick Corn Removers: 40% (9s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Extra-Thick Callus Removers: 40% (4s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Extra-Thick Callus Removers: 40% (4s) [includes 4 cushions]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; For Her Corn Removers: 40% (6s) [includes 6 cushions]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; OneStep Callus Removers: 40% (4s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; OneStep Corn Removers: 40% (6s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Small Corn Removers: 40% (9s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dr. Scholl's&reg; Ultra-Thin Corn Removers: 40% (9s) [includes 9 covers]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mosco&reg; One Step Corn Remover: 40% (8s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trans-Ver-Sal&reg;: 15% (10s, 25s) [20 mm PlantarPatch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trans-Ver-Sal&reg;: 15% (15s, 40s) [contains propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trans-Ver-Sal&reg;: 15% (12s, 40s) [contains propylene glycol; 12 mm AdultPatch]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical: 6% (177 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aliclen&trade;: 6% (177 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Beta Sal&reg;: 3% (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Denorex&reg; Extra Strength Protection: 3% (118 mL, 355 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DHS&trade; Sal: 3% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ionil Plus&reg;: 2% (240 mL) [conditioning shampoo]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ionil&reg;: 2% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LupiCare&reg; Dandruff: 2% (237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LupiCare&reg; Psoriasis: 2% (237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; Maximum Strength T/Sal&reg;: 3% (135 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     P&amp;S&reg;: 2% (118 mL, 236 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Salex&reg;: 6% (177 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; Deep Cleaning Micro-Bead Scrub: 3% (325 mL) [contains aloe, benzyl alcohol, moisturizers]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; Naturals Island Breeze: 3% (325 mL) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; Naturals Itchy Dry Scalp: 3% (207 mL, 325 mL) [contains aloe, benzyl alcohol, moisturizers]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thera-Sal: 3% (180 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo/Conditioner, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Denorex&reg; Extra Strength Protection 2-in-1: 3% (118 mL, 355 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermarest&reg; Psoriasis Medicated Shampoo/Conditioner: 3% (236 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Foam, Bar, Cream, gel, lotion, shampoo, soap",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: For external use only. Not for ophthalmic, oral, anal, or intravaginal use. When applying in concentrations &gt;10%, protect surrounding normal tissue with petrolatum",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topically for its keratolytic effect in controlling seborrheic dermatitis or psoriasis of body and scalp, dandruff, and other scaling dermatoses; removing excessive keratin in hyperkeratotic skin disorders (eg, verrucae, ichthyoses, keratosis palmaris and plantaris, keratosis pilaris, and pityriasis rubra pilaris); removing warts, corns, calluses; used in the treatment of acne",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F219808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Occlusal&trade;-HP may be confused with Ocuflox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F219807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning and irritation at site of exposure on normal tissue, peeling, scaling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Hyperventilation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to salicylic acid or any component; children &lt;2 years of age",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with eyes, face, lips, and other mucous membranes",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be used systemically due to severe irritating effect on GI mucosa; prolonged use over large areas, especially in children, may result in salicylate toxicity; do not apply on irritated, reddened, or infected skin; do not use on moles, birthmarks, warts with hair growing from them, or genital warts; topical liquid may contain tartrazine which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13386462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies when administered orally. Salicylates cross the placenta (Ostensen, 1998). Systemic absorption of topically applied salicylic acid varies depending on duration and vehicle (9% to 25%) (Akhavan, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of salicylate toxicity: Nausea, vomiting, dizziness, tinnitus, loss of hearing, lethargy, diarrhea, psychic disturbances",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces desquamation of hyperkeratotic epithelium; increases hydration of the stratum corneum causing the skin to swell, soften, and desquamate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Readily absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 5 hours when applied with an occlusive dressing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Salicyluric acid (52%), salicylate glucuronides (42%), and salicylic acid (6%) are the major metabolites identified in urine after percutaneous absorption",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F7741318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/17/16663?source=see_link\">",
"      see \"Topical salicylic acid: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform physician if redness or irritation occurs. Nursing mothers should not apply salicylic acid to the chest area or any area with which the nursing child&rsquo;s mouth may come in contact.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12778 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44038=[""].join("\n");
var outline_f43_0_44038=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219772\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219773\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049785\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049780\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219763\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219750\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049788\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049787\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219808\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219807\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049791\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049779\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049778\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300021\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219758\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219759\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386462\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049784\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049777\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049790\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7741318\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12778\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12778|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/23/30072?source=related_link\">",
"      Topical salicylic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/17/16663?source=related_link\">",
"      Topical salicylic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_0_44039="Hematologic manifestations of HIV infection: Neutropenia";
var content_f43_0_44039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematologic manifestations of HIV infection: Neutropenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/0/44039/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/0/44039/contributors\">",
"     Timothy J Friel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/0/44039/contributors\">",
"     David T Scadden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/0/44039/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/0/44039/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/0/44039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/0/44039/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/0/44039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shortly after the first description of the acquired immunodeficiency syndrome (AIDS), cytopenias of all major blood cell lines were increasingly recognized in patients with HIV infection. As an example, in one early series of patients with AIDS, anemia was noted in approximately 70 percent, lymphopenia in 70 percent, neutropenia in 50 percent, and thrombocytopenia in 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of the various cytopenias correlates directly with the degree of immunosuppression. As an example, the incidence of neutropenia varies from 5 to 10 percent in the early, asymptomatic stages of infection to as high as 50 to 70 percent of patients with advanced disease. The degree of neutropenia may be overestimated from the total white blood cell count due to the associated lymphopenia (as evidenced by the low CD4 cell count).",
"   </p>",
"   <p>",
"    However, isolated abnormalities, particularly thrombocytopenia, may be encountered as the initial presentation of human immunodeficiency virus (HIV) infection. As a result, HIV infection should be considered in the assessment of patients presenting with any type of cytopenia.",
"   </p>",
"   <p>",
"    This topic review will discuss the causes, clinical impact, and treatment of neutropenia in patients with HIV infection. Similar issues regarding anemia, thrombocytopenia, coagulation defects, and lymphopenia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3098?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14522?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia is defined as an absolute neutrophil count (ANC) of less than",
"    <span class=\"nowrap\">",
"     1500/microL.",
"    </span>",
"    The ANC is equal to the product of the white blood cell count (WBC) and the fraction of polymorphonuclear cells (PMNs) and band forms noted on the differential analysis:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;ANC = WBC",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    x percent (PMNs &nbsp;+ &nbsp;bands) &divide; 100",
"   </p>",
"   <p>",
"    Neutrophilic metamyelocytes and younger forms are not included in this calculation (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The risk of infection begins to increase at an ANC below",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    and becomes increasingly more severe when the ANC is",
"    <span class=\"nowrap\">",
"     &lt;500/microL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63903 \" href=\"mobipreview.htm?10/19/10555\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of neutropenia is often multifactorial in HIV-infected patients, representing the combined effects of systemic infection, medications, and HIV itself (",
"    <a class=\"graphic graphic_table graphicRef78610 \" href=\"mobipreview.htm?11/51/12092\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many therapies used in the management of HIV, associated opportunistic infections, and malignancies can lead to clinically significant neutropenia. In one prospective analysis, drugs were proposed as the primary cause of neutropenia in 50 of 62 patients (80 percent).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      (AZT),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      and combination chemotherapy for HIV-related malignancies are the most commonly implicated therapies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of highly active antiretroviral therapy (HAART) appears to be protective against the development of HIV-associated neutropenia, especially when using regimens not containing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/3\">",
"       3",
"      </a>",
"      ]. However, the incidence of neutropenia among antenatally exposed infants was greater among those whose mothers received HAART (22 percent) compared to those receiving AZT monotherapy (6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/4\">",
"       4",
"      </a>",
"      ]. This difference was only apparent during the first month of life and did not appear to have clinical significance.",
"     </li>",
"     <li>",
"      Any opportunistic infection or malignancy that infiltrates the bone marrow may result in cytopenia. Mycobacterium avium complex (MAC), Mycobacterium tuberculosis, Histoplasma capsulatum, and other disseminated fungi are the most common infectious agents capable of infiltrating the bone marrow.",
"     </li>",
"     <li>",
"      Lymphomas, especially small, noncleaved cell, non-Hodgkin lymphoma, can produce pancytopenia through diffuse bone marrow involvement.",
"     </li>",
"     <li>",
"      Acute Epstein-Barr virus infection, dengue fever, viral hepatitis, parvovirus B19, rickettsial disease, salmonella infection, leishmaniasis, and brucellosis may all be associated with depressed neutrophil counts. Due to frequent co-infections in HIV, these should be considered based upon the history, such as travel. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10473?source=see_link\">",
"       \"Infectious causes of neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cytomegalovirus infection can promote neutropenia through direct infection of marrow stromal elements and perhaps also myeloid cells.",
"     </li>",
"     <li>",
"      Significant geographic variability in the prevalence of neutropenia has been observed among different clinical cohorts. In the multinational AIDS Clinical Trial Group Prospective Evaluation of Antiretrovirals in Resource-Limited Settings Study (PEARLS), the prevalence of neutropenia (defined as an absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &le;1300/microL)",
"      </span>",
"      among more than 1500 participants demonstrated significant variability depending upon the country of origin of enrolled patients. This heterogeneity persisted after controlling for CD4 count, hemoglobin, platelet count, gender and ethnicity. Prevalences of neutropenia exceeding 15 percent were observed among patients from Malawi, Zimbabwe, Haiti, the United States, and South Africa; in contrast, the baseline prevalence of neutropenia was less than 5 percent among patients enrolled from India and Peru [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antineutrophil antibodies have been detected using a granulocyte immunofluorescence test in almost one-third of patients with HIV. However, the presence of these antibodies does not correlate with the ANC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/6\">",
"       6",
"      </a>",
"      ]. Thus, autoimmune destruction is not thought to play an important role in the pathogenesis of clinically significant neutropenia. The high prevalence of these antibodies may be secondary to the immune dysregulation and hyperglobulinemia frequently seen in patients with AIDS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these secondary causes, HIV itself is a likely mediator of abnormal hematopoiesis in all cell lines. Many mechanisms have been proposed, including direct infection of early hematopoietic precursors, aberrations of local cytokine and growth factor signaling, and changes in the bone marrow stroma. As an example, early myeloid progenitor cells from healthy subjects display blunted replication when cocultured with the bone marrow of HIV-infected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, circulating levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) in HIV-positive patients are depressed when compared with healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IMPACT OF NEUTROPENIA IN PATIENTS WITH HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIV infection are more susceptible to serious, often life-threatening bacterial infections of many types, including bacteremia, pneumonia, meningitis, colitis and soft tissue infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .) They are also at greater risk for invasive fungal infections with organisms such as Candida albicans, Cryptococcus neoformans, Histoplasma capsulatum and Coccidioides immitis. Invasive fungal infections are seen more frequently in patients with reduced circulating neutrophil counts; Candida and Aspergillus are common pathogens in this setting. Many factors have been linked to these increased risks among HIV patients, including impaired cellular immunity, frequent usage of central venous catheters, altered mucosal integrity, and injection drug use (IDU).",
"   </p>",
"   <p>",
"    Several case studies failed to definitively link neutropenia in HIV-infected patients with the development of subsequent bacterial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Other data, however, suggest that a propensity for infection accompanies a decline in ANC. The range of findings can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control comparison between 118 neutropenic and 118 non-neutropenic patients with AIDS matched for baseline CD4 cell counts found an adjusted relative risk for infection of 2.3 and 7.9 at ANCs below 1000 and",
"      <span class=\"nowrap\">",
"       500/microL,",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/11\">",
"       11",
"      </a>",
"      ]. The incidence of serious bacterial infections increased with diminishing ANCs, although reduced neutrophil counts did not correlate with the development of infections at any specific site.",
"     </li>",
"     <li>",
"      In another case-control study, the incidence of bacteremia was increased 14-fold in patients with ANCs below",
"      <span class=\"nowrap\">",
"       1000/microL",
"      </span>",
"      (13 versus 0.9 per 100 patient months in patients with higher ANCs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/12\">",
"       12",
"      </a>",
"      ]. Multivariate analysis demonstrated that neutropenia (odds ratio [OR] 22.6) and the presence of a central venous catheter (OR 8.5) were the only significant risk factors.",
"     </li>",
"     <li>",
"      Using statistics from the San Francisco General Hospital outpatient database, an observational study documented an increased frequency of hospitalizations among HIV-infected patients with at least one prior episode of neutropenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/13\">",
"       13",
"      </a>",
"      ]. There was a seven- to 10-fold greater risk of hospitalization among patients with nadir ANCs below",
"      <span class=\"nowrap\">",
"       500/microL,",
"      </span>",
"      compared with those whose nadirs fell into the 1000 to",
"      <span class=\"nowrap\">",
"       1500/microL",
"      </span>",
"      range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of neutropenia on overall mortality of patients with HIV infection remains unclear. Prospective data from the Women's Interagency HIV Study, a multicenter, longitudinal project assessing the medical course of over 2000 HIV-infected females and approximately 570 HIV-uninfected controls throughout the United States, failed to demonstrate any reduction in overall mortality among women with neutropenia defined as either an ANC",
"    <span class=\"nowrap\">",
"     &lt;1000/microL",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     &lt;2000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/3\">",
"     3",
"    </a>",
"    ]. In this cohort, neutropenia was relatively common, with 31 and 79 percent of the women experiencing at least one episode of ANC &lt;1000 or &lt;2000, respectively, during 7.5 years of follow-up.",
"   </p>",
"   <p>",
"    Neutropenia has been associated with increased morbidity and mortality among patients presenting with either febrile neutropenia or focal infections in several retrospective reviews, although the cause of neutropenia does not appear to be important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/14\">",
"     14",
"    </a>",
"    ]. A retrospective survey, for example, evaluated 350 HIV-infected patients with pneumonia, 17 percent of whom had an ANC below",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/15\">",
"     15",
"    </a>",
"    ]. The case-fatality rate of 77 percent among the neutropenic patients exceeded that in patients with CD4 counts below",
"    <span class=\"nowrap\">",
"     100/microL",
"    </span>",
"    (36 percent) or hypoxemia (pO2 less than 70 mmHg) (58 percent).",
"   </p>",
"   <p>",
"    In another retrospective assessment of 1077 cases of blood stream infections among HIV-infected patients, the presence of neutropenia was an independent risk factor for increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ADMINISTRATION OF G-CSF OR GM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal hematopoiesis is regulated by endogenous growth factors and cytokines. These glycoprotein hormones promote the proliferation of progenitor stem cells into increasingly differentiated cells and enhance the activity of mature blood cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .) Two endogenous glycoproteins &mdash; granulocyte-macrophage colony-stimulating factor (GM-CSF) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) &mdash; are major regulators of myelopoiesis, controlling the differentiation, proliferation, and functional activity of cells in the myeloid line.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GM-CSF stimulates various components of the myeloid line, especially neutrophils, monocytes and eosinophils [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/17\">",
"       17",
"      </a>",
"      ]. It also regulates multiple cellular functions, such as the inhibition of neutrophil migration and enhancement of the oxidative metabolism, chemotaxis, antibody-dependent cellular cytotoxicity and phagocytosis in mature neutrophils and macrophages [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       Granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) more specifically exerts its control on the differentiation and functional capabilities of neutrophils, although stem cells also have G-CSF receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both G-CSF and GM-CSF have an important role in the mobilization of stem cells from the bone marrow into the peripheral circulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability to synthesize these glycoproteins in commercial amounts has provided physicians with a means of reversing neutropenia in many settings. Given the frequency of reduced neutrophil counts and function in HIV-infected individuals, the role of recombinant growth factors in this setting has been extensively evaluated. Many studies have demonstrated the utility of recombinant G-CSF (G-CSF) and recombinant GM-CSF (GM-CSF) in boosting the ANC in these patients. The long-term impact of these factors on overall mortality remains debated and is the subject of ongoing investigation. The most important intervention in patients with neutropenia is to discontinue implicated drugs. Growth factors are indicated only if concurrent drugs are not implicated and are considered crucial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment with G-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of G-CSF have been established through multiple clinical trials in patients with HIV-associated neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. The efficacy and safety of G-CSF was evaluated in 200 patients enrolled in an open-label, multicenter trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/20\">",
"     20",
"    </a>",
"    ]. All patients had an absolute neutrophil count (ANC) less than",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    on more than three occasions during a two-week period; no causes of neutropenia were excluded from the trial.",
"   </p>",
"   <p>",
"    The patients received 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day of G-CSF subcutaneously for 28 days; escalation to a maximum of 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day was permitted to maintain an ANC greater than",
"    <span class=\"nowrap\">",
"     2000/microL.",
"    </span>",
"    After 28 days, patients received maintenance dosing of 300",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    one to seven days per week to maintain the targeted ANC. Neutropenia resolved in 98 percent of patients; this occurred after two days in more than one-half of these patients. During the maintenance phase of the study, normal neutrophil counts were supported by a median G-CSF dose of 300 mcg three times per week. Eighty-three percent of the patients enrolled in this study were also taking myelosuppressive agents such as AZT,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . No patient had to discontinue or reduce the dose of these agents during the course of the study, although most physicians would use readily available drug alternatives not associated with neutropenia in order to avoid the cost and inconvenience of subcutaneous injections of G-CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These benefits were confirmed in an open-label, placebo-controlled multicenter trial assessing G-CSF in over 250 patients with CD4 cell counts less than",
"    <span class=\"nowrap\">",
"     200/microL",
"    </span>",
"    and ANCs between 750 and",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with malignancy or chemotherapy-associated neutropenia were excluded. Patients in this study were randomly assigned to receive intermittent or daily therapy with rG-CSF or placebo. In the intermittent therapy arm, patients received 300 mcg three times a week; dose escalation to a maximum of 600 mcg daily was permitted to attain a target ANC of 2000 to",
"    <span class=\"nowrap\">",
"     10,000/microL.",
"    </span>",
"    In the daily dosing arm, patients initially received 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day with gradual escalation to a maximum dose of 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day to achieve the same targeted ANC. Patients in the placebo group underwent a second random assignment to receive G-CSF if persistent neutropenia developed. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary endpoints included severe neutropenia (ANC less than",
"      <span class=\"nowrap\">",
"       500/microL",
"      </span>",
"      in two consecutive measurements) and death during the 24-week study. The likelihood of reaching a primary endpoint was significantly lower with G-CSF therapy (8.2 and 12.8 percent in the intermittent and daily dosing groups, respectively, versus 34.1 percent in the control groups, p&lt;0.002).",
"     </li>",
"     <li>",
"      Patients receiving G-CSF developed approximately 30 percent fewer bacterial infections and required 45 percent fewer hospital days for bacterial infections when compared with controls. The magnitude of these changes (approximately 1.3 fewer events and 10 fewer hospital days per 1000 patient days) was modest relative to the expense.",
"     </li>",
"     <li>",
"      There were no differences in mortality between treatment arms. The last finding is an important issue. Although reduced mortality in neutropenic patients treated with G-CSF has been suggested in retrospective, case-control trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/24\">",
"       24",
"      </a>",
"      ], no prospective trial has confirmed improved long-term survival in HIV-infected patients who receive G-CSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Effect on neutrophil function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Qualitative improvements in neutrophil function may also be observed following use of G-CSF. In one study, for example, a single dose of 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    in HIV-infected subjects produced a 3 to 11-fold increase in ANC after 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/25\">",
"     25",
"    </a>",
"    ]. Polymorphonuclear cells obtained from these patients exhibited augmented fungicidal activity and production of superoxide anions when incubated with Candida albicans and Cryptococcus neoformans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Effect on CD4 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on the effect of G-CSF on the CD4 count. Both a transient increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/26\">",
"     26",
"    </a>",
"    ] and no change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/23\">",
"     23",
"    </a>",
"    ] have been described. The percentage of CD4 + lymphocytes is generally unchanged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;G-CSF is generally well-tolerated although musculoskeletal complaints (especially bone pain) occur in as many as 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/20\">",
"     20",
"    </a>",
"    ]. Other side effects include dysuria and local reactions at the administration site. Mild elevations in serum aminotransferases, lactate dehydrogenase, and uric acid have also been described. Tachyphylaxis does not accompany long-term use.",
"   </p>",
"   <p>",
"    Stimulation of HIV replication or an acceleration of disease progression during therapy has generally not been observed. However, a preliminary report from a study in which G-CSF was given to mobilize stem cells found transient HIV RNA increases in approximately 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/27\">",
"     27",
"    </a>",
"    ]. This appears to be a more important issue with GM-CSF (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Usage guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since there is no proven mortality benefit from G-CSF, the use of this expensive agent has not been recommended as a \"standard of care\" in all neutropenic HIV-infected patients according to the",
"    <span class=\"nowrap\">",
"     CDC/IDSA",
"    </span>",
"    guidelines (MMWR August 27, 1999). G-CSF therapy may be justified in patients at high risk for the development of serious bacterial infection (eg, primarily severe neutropenia, indwelling venous catheters, prior serious infections) and those with documented bacterial infection. Its use in patients receiving chemotherapy for a malignancy should be guided by the same principles as in the non-HIV infected population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical starting dose of rG-CSF is 1 to 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day subcutaneously; the dose can be escalated every three days to a maximum of 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day. Response in ANC is generally evident in 48 hours. After the ANC reaches the targeted range of 1000 to",
"    <span class=\"nowrap\">",
"     2000/microL,",
"    </span>",
"    maintenance therapy with 300 mcg three times each week is common; however, the dose required to maintain the target ANC varies markedly among patients from one to seven doses per week.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/28/12741?source=see_link\">",
"     Pegfilgrastim",
"    </a>",
"    , a long-acting colony stimulating factor formed by the conjugation of G-CSF with a 20-kD",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    moiety, has been approved for the prophylaxis of chemotherapy-induced neutropenia. Its role in the management of HIV-associated neutropenia has not been defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment with GM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beneficial impact of recombinant GM-CSF on neutropenia has been well described among patients with HIV. Given its effects on a broad range of blood cells, increases in neutrophils, monocytes, eosinophils and, least commonly, lymphocytes are characteristic of therapy. Like G-CSF, GM-CSF has demonstrated efficacy in improving the hematologic tolerance of many therapies, including AZT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/29\">",
"     29",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/30\">",
"     30",
"    </a>",
"    ], and combination chemotherapy regimens for non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/31\">",
"     31",
"    </a>",
"    ] and Kaposi's sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The starting dose of GM-CSF is generally 250",
"    <span class=\"nowrap\">",
"     mcg/day.",
"    </span>",
"    Dose modifications and maintenance schedules are identical to those for G-CSF (with doses between 5 to 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day administered one to seven days a week, titrated to patient response and tolerance).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the efficacy of GM-CSF, G-CSF is more widely used due to its more favorable toxicity profile and the theoretical concern of GM-CSF increasing HIV replication. Flu-like symptoms, especially fatigue, anorexia, headache, myalgias, chills and fever are the most frequently noted side effects of GM-CSF. Like G-CSF, bone pain is also reported and may reflect expansion of the marrow by the synthetic growth factor. Eosinophilia is common, while exacerbations of thrombocytopenia and anemia (possibly reflecting a granulocyte \"steal\" phenomenon) may be infrequently seen. Tachyphylaxis has not been observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Possible stimulation of HIV replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major concern with GM-CSF therapy is the potential for stimulation of HIV replication. This phenomenon was initially demonstrated during in vitro experiments with mononuclear phagocytes exposed to GM-CSF or IL-3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/33\">",
"     33",
"    </a>",
"    ]. Later in vitro studies revealed upregulation of CCR5 coreceptor expression and enhanced HIV infectivity in fresh human monocytes exposed to GM-CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vivo data on the relationship between GM-CSF therapy and HIV replication have been conflicting. In a randomized trial of HIV-infected patients receiving CHOP chemotherapy for non-Hodgkin lymphoma, with or without GM-CSF, HIV p24 antigenemia increased initially in the GM-CSF treated group compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/31\">",
"     31",
"    </a>",
"    ]. By the end of the study, however, there were no differences between the groups. Comparable increases in p24 antigenemia have been cited with GM-CSF recipients in the absence of concomitant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast to these findings, other studies failed to demonstrate any alterations of HIV replication after exposure to GM-CSF in the context of concurrent AZT therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/32,36\">",
"     32,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro studies suggested that GM-CSF might enhance thymidine kinase activity and therefore potentiate the anti-HIV effects of AZT. However, a trial to test this phenomenon in patients failed to demonstrate any potentiation of the AZT effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44039/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8741991\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of neutropenia in HIV-infected subjects varies from 5 to 10 percent in the early, asymptomatic stages of infection to as high as 50 to 70 percent of patients with advanced disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of neutropenia  The causes of neutropenia in the HIV-infected subject include use of anti-viral and anti-bacterial medications that suppress granulocyte production, opportunistic infections, concomitant malignancy, and alterations secondary to infection with HIV itself (",
"      <a class=\"graphic graphic_table graphicRef78610 \" href=\"mobipreview.htm?11/51/12092\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Impact of neutropenia  A propensity for infection accompanies a decline in the absolute neutrophil count (ANC) in subjects with HIV infection (",
"      <a class=\"graphic graphic_table graphicRef63903 \" href=\"mobipreview.htm?10/19/10555\">",
"       table 1",
"      </a>",
"      ). The presence of neutropenia is also an independent risk factor for increased mortality. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Impact of neutropenia in patients with HIV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment  Recombinant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) and recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) increase the ANC in HIV-infected subjects and reduce the incidence of infection and hospitalization, although their effect on overall mortality is unclear. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Administration of G-CSF or GM-CSF'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most important intervention in HIV-infected patients with neutropenia is to discontinue implicated drugs. Use of G-CSF or GM-CSF is indicated only if concurrent drugs are not implicated in the neutropenia. G-CSF therapy may be justified in patients at high risk for the development of serious bacterial infection and those with documented bacterial infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Usage guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We prefer G-CSF over GM-CSF because of a better side effect profile for G-CSF.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/1\">",
"      Zon LI, Arkin C, Groopman JE. Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol 1987; 66:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/2\">",
"      Meynard JL, Guiguet M, Arsac S, et al. Frequency and risk factors of infectious complications in neutropenic patients infected with HIV. AIDS 1997; 11:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/3\">",
"      Levine AM, Karim R, Mack W, et al. Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study. Arch Intern Med 2006; 166:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/4\">",
"      Bae WH, Wester C, Smeaton LM, et al. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. AIDS 2008; 22:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/5\">",
"      Firnhaber C, Smeaton L, Saukila N, et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis 2010; 14:e1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/6\">",
"      Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 1987; 66:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/7\">",
"      Leiderman IZ, Greenberg ML, Adelsberg BR, Siegal FP. A glycoprotein inhibitor of in vitro granulopoiesis associated with AIDS. Blood 1987; 70:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/8\">",
"      Mauss S, Steinmetz HT, Willers R, et al. Induction of granulocyte colony-stimulating factor by acute febrile infection but not by neutropenia in HIV-seropositive individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/9\">",
"      Krumholz HM, Sande MA, Lo B. Community-acquired bacteremia in patients with acquired immunodeficiency syndrome: clinical presentation, bacteriology, and outcome. Am J Med 1989; 86:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/10\">",
"      Fichtenbaum CJ, Woeltje KF, Powderly WG. Serious Pseudomonas aeruginosa infections in patients infected with human immunodeficiency virus: a case-control study. Clin Infect Dis 1994; 19:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/11\">",
"      Moore RD, Keruly JC, Chaisson RE. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 1995; 155:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/12\">",
"      Keiser P, Higgs E, Smith J. Neutropenia is associated with bacteremia in patients infected with the human immunodeficiency virus. Am J Med Sci 1996; 312:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/13\">",
"      Jacobson MA, Liu RC, Davies D, Cohen PT. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med 1997; 157:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/14\">",
"      Hambleton J, Arag&oacute;n T, Modin G, et al. Outcome for hospitalized patients with fever and neutropenia who are infected with the human immunodeficiency virus. Clin Infect Dis 1995; 20:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/15\">",
"      Tumbarello M, Tacconelli E, de Gaetano K, et al. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/16\">",
"      Ortega M, Almela M, Soriano A, et al. Bloodstream infections among human immunodeficiency virus-infected adult patients: epidemiology and risk factors for mortality. Eur J Clin Microbiol Infect Dis 2008; 27:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/17\">",
"      Groopman JE, Mitsuyasu RT, DeLeo MJ, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987; 317:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/18\">",
"      Baldwin GC, Gasson JC, Quan SG, et al. Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci U S A 1988; 85:2763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/19\">",
"      Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/20\">",
"      Hermans P, Rozenbaum W, Jou A, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group. AIDS 1996; 10:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/21\">",
"      Miles SA, Mitsuyasu RT, Moreno J, et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991; 77:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/22\">",
"      Garavelli PL, Berti P. Efficacy of recombinant granulocyte colony-stimulating factor in the long-term treatment of AIDS-related neutropenia. AIDS 1993; 7:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/23\">",
"      Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998; 12:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/24\">",
"      Keiser P, Rademacher S, Smith JW, et al. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients. Am J Med 1998; 104:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/25\">",
"      Vecchiarelli A, Monari C, Baldelli F, et al. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis 1995; 171:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/26\">",
"      Nielsen SD, Afzelius P, Dam-Larsen S, et al. Effect of granulocyte colony-stimulating factor (G-CSF) in human immunodeficiency virus-infected patients: increase in numbers of naive CD4 cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy. J Infect Dis 1998; 177:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/27\">",
"      Schooley RT, Mladenovic J, Sevin A, et al. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis 2000; 181:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/28\">",
"      Ozer H. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors. Curr Opin Hematol 1996; 3:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/29\">",
"      Levine JD, Allan JD, Tessitore JH, et al. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. Blood 1991; 78:3148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/30\">",
"      Hardy WD. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. J Acquir Immune Defic Syndr 1991; 4 Suppl 1:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/31\">",
"      Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991; 9:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/32\">",
"      Scadden DT, Bering HA, Levine JD, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991; 9:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/33\">",
"      Koyanagi Y, O'Brien WA, Zhao JQ, et al. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988; 241:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/34\">",
"      Wang J, Roderiquez G, Oravecz T, Norcross MA. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol 1998; 72:7642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/35\">",
"      Pluda JM, Yarchoan R, Smith PD, et al. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood 1990; 76:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/36\">",
"      Davey RT Jr, Davey VJ, Metcalf JA, et al. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 1991; 164:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44039/abstract/37\">",
"      Scadden DT, Pickus O, Hammer SM, et al. Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996; 12:1151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8376 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-86B232FEE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44039=[""].join("\n");
var outline_f43_0_44039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8741991\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IMPACT OF NEUTROPENIA IN PATIENTS WITH HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ADMINISTRATION OF G-CSF OR GM-CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment with G-CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Effect on neutrophil function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Effect on CD4 cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Usage guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment with GM-CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Possible stimulation of HIV replication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8741991\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8376\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8376|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/19/10555\" title=\"table 1\">",
"      Neutropenia and infectious risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/51/12092\" title=\"table 2\">",
"      Causes of neutropenia in HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3098?source=related_link\">",
"      Hematologic manifestations of HIV infection: Anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14522?source=related_link\">",
"      Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10473?source=related_link\">",
"      Infectious causes of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_0_44040="Parallelogram mastectomy";
var content_f43_0_44040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Parallelogram mastectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 692px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parallelogram partial mastectomy, upper pole cancer preoperative, and intraoperative images.",
"    <br>",
"     (A) Preoperative target marking and placement of parallelogram.",
"     <br>",
"      (B) Intraoperative marking with patient in supine position.",
"      <br>",
"       (C) Initial skin incision revealing wide exposure over target lesion.",
"       <br>",
"        (D) Full-thickness dissection posteriorly to chest wall to facilitate delivery of target lesion.",
"        <br>",
"         (E) Inked resected specimen.",
"         <br>",
"          (F) Deep broglandular closure using mastopexy advancement technique to close breast tissue over exposed muscle.",
"          <br>",
"           (G) Final wound closure.",
"           <div class=\"footnotes\">",
"           </div>",
"           <div class=\"reference\">",
"            Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"           </div>",
"           <div class=\"contractual\">",
"            <br/>",
"            <a href=\"file://www.lww.com\">",
"             file://www.lww.com",
"            </a>",
"           </div>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44040=[""].join("\n");
var outline_f43_0_44040=null;
var title_f43_0_44041="Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome";
var content_f43_0_44041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of pregnant women with antiphospholipid antibodies or the antiphospholipid syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/0/44041/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/0/44041/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/0/44041/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/0/44041/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/0/44041/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/0/44041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/0/44041/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/0/44041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid syndrome (APS) is characterized by vascular thrombosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pregnancy complications in association with laboratory evidence of antiphospholipid antibodies (aPL).",
"   </p>",
"   <p>",
"    The management of pregnant women with APS or aPL is discussed in this topic review. Pregnancy complications and general issues related to APS and aPL, including selection of patients for diagnostic testing, are reviewed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41000?source=see_link\">",
"       \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27096?source=see_link\">",
"       \"Diagnosis of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link\">",
"       \"Treatment of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/16/35081?source=see_link\">",
"       \"Pathogenesis of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF INITIAL TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several treatment regimens have been proposed to prevent maternal thrombotic complications and improve pregnancy outcome in women with APS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/1\">",
"     1",
"    </a>",
"    ]. Interpretation of studies in this area is difficult due to a lack of well-designed trials and to the clinical complexity of the syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its antiplatelet effects, low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (ASA) (50 to 100 mg) enhances leukocyte-derived interleukin-3 production, which stimulates normal trophoblast growth and hormone expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/2\">",
"     2",
"    </a>",
"    ]. For prevention of fetal loss in women with APS, administration of low dose ASA alone has been associated with an increased frequency of successful pregnancy outcome in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/3\">",
"     3",
"    </a>",
"    ], but was no better than supportive care in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. If the patient takes a nonsteroidal anti-inflammatory drug (NSAID) for pain in the first two trimesters, it is best to wait at least three hours after the ASA dose before taking the NSAID.",
"   </p>",
"   <p>",
"    Low dose ASA can be stopped anytime after 36 weeks of gestation, and, ideally, should be stopped 7 to 10 days before delivery because some studies have reported a slight increase in mostly minor perioperative bleeding with continuation of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/5\">",
"     5",
"    </a>",
"    ]. In women with a past history of serious arterial thrombotic complications, such as stroke or myocardial infarction, the potential benefit of continuing ASA through labor and delivery outweighs the small risk of incisional bleeding. Use of low dose ASA has not been associated with either premature closure of the ductus arteriosus or increase in significant postpartum hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heparin/heparin with aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    has several effects that may help prevent thromboembolic events and pregnancy loss:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antithrombotic effects include potentiating the anti-thrombin effects of antithrombin and other endogenous antithrombin effectors, increasing levels of factor Xa inhibitor, and inhibiting platelet aggregation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H2#H2\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Use of heparin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      may also bind to aPLs and render them inactive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Experiments in mice suggested that complement activation might be an essential component of aPL mediated decidual and placental injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. In a mouse model, low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      prevented aPL associated fetal loss by inhibiting complement activation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      may also block tissue factor-mediated placental bed immunopathology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Like unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight heparins (LMWH) inactivate factor Xa, but they have a lesser effect on thrombin. As a result, LMWHs do not prolong the aPTT. Potential advantages of LMWH over unfractionated heparin are once daily dosing and lower risks of hemorrhage, thrombocytopenia, and osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H29#H29\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Use of LMW heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subcutaneous administration of either unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin (LMWH) has been used to treat pregnant women with APS. A number of studies have demonstrated successful pregnancy outcomes in women treated with these heparins at various doses either alone or with low dose ASA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/3,13-22\">",
"     3,13-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three meta-analyses of randomized trials in women with APS concluded the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and ASA significantly reduced pregnancy loss (RR 0.46, 95% CI 0.29-0.71) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/1\">",
"     1",
"    </a>",
"    ] or first trimester pregnancy loss (OR 0.39, 95% CI 24-0.65) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/23\">",
"     23",
"    </a>",
"    ] and increased live births (RR 1.3, 95% CI 1.04-1.63) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/24\">",
"     24",
"    </a>",
"    ] compared to ASA alone. However, there are several limitations to these analyses, including the small number of trials, the small sample size in each trial, and the low quality of the trials themselves. For example, information about patient dropout and some adverse outcomes was not always available and",
"    <span class=\"nowrap\">",
"     patients/providers",
"    </span>",
"    were not blinded to the treatment. Both therapies were associated with relatively high live birth rates ranging from 71 to 84 percent for combined therapy and 42 to 80 percent for ASA alone. If there is an improvement in outcome with combined therapy versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone, the difference appears to be modest at best. Further investigation is needed to determine whether there is a true benefit from combined therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Unfractionated versus LMW heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited information from randomized trials on pregnancy outcome with use of LMWH versus unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . A small pilot trial reported 9 of 13 women given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    had a successful pregnancy compared to 4 of 13 women given unfractionated heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/25\">",
"     25",
"    </a>",
"    ]. Observational studies in pregnant women have also shown a benefit of LMWH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/26\">",
"     26",
"    </a>",
"    ], but a meta-analysis of two randomized trials did not show a reduction in late fetal loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the paucity of data from randomized trials of pregnant women with APS, data from other patient populations have shown that LMWH is as effective as unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with the advantages stated above. There is no reason to think that this would not also be true in pregnant women with APS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44846195\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids (and other cytotoxic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) are of no proven utility in nonpregnant individuals with the APS. Levels of aPL appear to be relatively resistant to immunosuppressive therapy and there is little evidence that these drugs alter the course of the hypercoagulable state.",
"   </p>",
"   <p>",
"    Studies evaluating the efficacy of glucocorticoids for reducing the risk of adverse pregnancy outcomes have yielded conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/1,13,14,27-30\">",
"     1,13,14,27-30",
"    </a>",
"    ]. However, an increased risk of adverse obstetrical and maternal consequences of steroid therapy, including premature rupture of membranes, preterm delivery, fetal growth restriction, infection, preeclampsia, gestational diabetes, maternal osteopenia (especially when used with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ), and avascular necrosis, have been demonstrated consistently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/14,27-29,31\">",
"     14,27-29,31",
"    </a>",
"    ], and have led to abandonment of this approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paucity of data from large, well designed trials of different management options in comparable groups of pregnant women with this complex disease contributes to the difficulty in formulating recommendations for managing these pregnancies. Our approach is guided by the discussion above, additional observational studies, personal experience, and the opinions of others experienced in the management of such women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. Our recommendations are presented in the context of particular combinations of laboratory and clinical features, and generally consistent with recommendations of the American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local reference standards should be checked when interpreting titers. Unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and low molecular weight heparin dosing and monitoring are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link&amp;anchor=H7898432#H7898432\">",
"     \"Inherited thrombophilias in pregnancy\", section on 'Dose and duration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     APS based on aCL and prior thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with laboratory criteria for aPL and a prior history of arterial or venous thrombosis are at high risk of recurrence and are generally on lifelong anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These women should receive thromboprophylaxis during pregnancy and postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/38\">",
"     38",
"    </a>",
"    ]. Management of thromboprophylaxis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If these women also have a history of APS-defining pregnancy complications, we treat them with both LMWH and low dose ASA during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20154608\">",
"    <span class=\"h2\">",
"     APS based on aCL and pregnancy-related clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally offer treatment (described below) to pregnant women with APS based on laboratory and pregnancy-related clinical criteria, but no history of venous or arterial thrombosis. Some experts consider both close clinical surveillance and pharmacologic prophylaxis reasonable approaches in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     One or more late fetal losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with laboratory criteria for aPL and one or more fetal losses after 10 weeks of gestation, we suggest combined therapy with low dose ASA (81 mg per day begun as soon as conception is attempted) and prophylactic LMWH; low dose ASA and prophylactic or intermediate dose unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is a reasonable alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/1,32,37-40\">",
"     1,32,37-40",
"    </a>",
"    ]. A meta-analysis suggested that prophylactic use of heparin and low-dose ASA may reduce the risk of pregnancy loss in these women by 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Heparin/LMWH",
"    </span>",
"    is begun upon confirmation of intrauterine pregnancy. Heparin and LMWH dosing in pregnancy are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link&amp;anchor=H7898432#H7898432\">",
"     \"Inherited thrombophilias in pregnancy\", section on 'Dose and duration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, we prefer LMWH to unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , as LMWH has the advantages of once a day dosing and lower risks of hemorrhage, thrombocytopenia, and osteoporosis, although it is generally more expensive than unfractionated heparin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    -induced osteoporosis with fracture has been reported as a complication in up to 2 percent of pregnant women on long-term heparin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/41\">",
"     41",
"    </a>",
"    ]. Recovery of bone density occurs postpartum after the heparin is discontinued; it is unclear, however, if the recovery is complete. Supplemental calcium (1000 mg elemental calcium per day), vitamin D (800 international units), and weight bearing activity (eg, walking, lifting weights) are recommended to minimize the severity of bone loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=see_link\">",
"     \"Drugs that affect bone metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Recurrent embryonic losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of women with laboratory criteria for aPL and multiple embryonic losses (less than 10 weeks of gestation) is controversial, as there are many causes of early recurrent pregnancy loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/6/8298?source=see_link\">",
"     \"Definition and etiology of recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a paucity of data addressing management of these women (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Heparin/heparin with aspirin'",
"    </a>",
"    above). If the woman has had three or more such losses and a structurally normal uterus and documentation of euploid losses, then we offer her low dose ASA and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy or low dose ASA and LMWH during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/38\">",
"     38",
"    </a>",
"    ]. ASA is begun as soon as conception is attempted and",
"    <span class=\"nowrap\">",
"     heparin/LMWH",
"    </span>",
"    is begun upon confirmation of intrauterine pregnancy. Heparin and LMWH dosing in pregnancy are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link&amp;anchor=H7898432#H7898432\">",
"     \"Inherited thrombophilias in pregnancy\", section on 'Dose and duration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Early and severe preeclampsia or growth restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest low dose ASA therapy beginning at the end of the first trimester and continuing in the second and third trimesters for women with laboratory criteria for aPL and a history of preterm delivery less than 34 weeks necessitated by early and severe preeclampsia or fetal growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41609?source=see_link\">",
"     \"Prevention of preeclampsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We may prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or LMWH with low dose ASA in cases of ASA failure or when placental examination shows extensive decidual inflammation and vasculopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombosis, although this approach has not been validated by a randomized trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     aCL or lupus anticoagulant alone without clinical criteria for APS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data upon which to guide management of pregnant women with the incidental finding of persistent presence of aCL or LA, without meeting any of the clinical criteria for APS. Over 50 percent of such women will have a successful pregnancy without medical treatment (ASA,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , LMWH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/27,42,43\">",
"     27,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapeutic options for these women include no therapy, low dose ASA alone, or low dose ASA and prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/39\">",
"     39",
"    </a>",
"    ]. Treatment decisions should be made on an individual basis. We agree with the majority of the Advisory Board of the 10th International Congress on aPL who favored using low dose ASA alone in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/32\">",
"     32",
"    </a>",
"    ]. Anticoagulation, if used, should begin in the first trimester after confirmation of intrauterine pregnancy",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     In vitro fertilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not prescribe prophylactic antithrombotic therapy during in vitro fertilization (IVF) for women with aCL or lupus anticoagulant antibodies but no clinical criteria for APS. The presence of aPL alone does not appear to adversely affect pregnancy rates or outcome in patients who are undergoing IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. A meta-analysis by the American Society for Reproductive Medicine (ASRM) Practice Committee concluded that assessment of aPL was not indicated among couples undergoing IVF and treatment was not justified in this population based upon existing data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. However, this issue remains controversial because of the heterogeneity of these studies and the different aCL assay methodologies used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. As an example, the American Society for Reproductive Immunology Antiphospholipid Antibody Committee strongly disagreed with the ASRM recommendation and called for studies to determine whether there are circumstances when evaluation and treatment of women with aPL undergoing fertility therapy are important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Postpartum women",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no high quality data to guide postpartum management of women with aPL but no history of prior thrombosis. Whether to begin or continue anticoagulation in all or selected groups of these women is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/51\">",
"     51",
"    </a>",
"    ]. The American College of Chest Physicians Evidence-Based Clinical Practice Guidelines concluded women with aPL and no personal or family history of thrombosis are probably not at increased risk of developing pregnancy-related venous thrombosis, but suggested postpartum anticoagulation for those with a family history of thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or LMWH antepartum because of prior late fetal loss or recurrent embryonic losses, we continue anticoagulation postpartum. Unfractionated heparin (5000 units every 12 hours) is administered beginning 12 hours post-cesarean delivery and four to six hours post-vaginal birth if there is no significant bleeding, and either continued or replaced with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (stopping the heparin when the INR is therapeutic) for six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. We also continue low dose ASA postpartum for six weeks.",
"   </p>",
"   <p>",
"    The Nimes Obstetricians and Hematologists Antiphospholipid Syndrome study followed women with APS based on obstetric history and no history of thrombosis for a median of 9.3 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/52\">",
"     52",
"    </a>",
"    ]. Compared to women with no thrombophilia, these women were at increased lifetime risk of deep vein thrombosis (adjusted hazard ratio 1.85, 95% CI 1.50-2.28; annualized rate 1.46 percent) and stroke (aHR 2.10, 95% CI 1.08-4.08; annualized rate 0.17 percent). Although not specifically studied, these women would likely be at particularly high risk postpartum, given that the postpartum state is a risk factor for thromboembolic events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link&amp;anchor=H7898370#H7898370\">",
"     \"Inherited thrombophilias in pregnancy\", section on 'Anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with aPL should avoid estrogen containing hormonal contraceptives (",
"    <a class=\"graphic graphic_table graphicRef64282 \" href=\"mobipreview.htm?26/8/26752\">",
"     table 1",
"    </a>",
"    ), which appear to work synergistically with aPL to increase the risk of arterial thrombotic events. In RATIO (Risk of Arterial Thrombosis In relation to Oral contraceptives), a multicentre population-based case-control study, the odds of ischemic stroke in women who took oral contraceptives and had lupus anticoagulant was OR 201 (95% CI 22.1-1828) versus OR 2.9 (95% CI 1.8-4.6) in oral contraceptive users without lupus anticoagulant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/53\">",
"     53",
"    </a>",
"    ]. The risk of myocardial infarction was also increased significantly in oral contraceptive users with lupus anticoagulant. The reference group included matched women without lupus anticoagulant or oral contraceptive use. Interestingly, there was no significant increase in risk of stroke in women with anticardiolipin IgG alone. A limitation of this study was that only 30 of 175 stroke patients and only six of 203 patients with myocardial infarction had lupus anticoagulant and, of these women, oral contraceptives were used by only 18 and 4 women, respectively. There was also no information on how many patients had systemic lupus erythematosus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16646?source=see_link\">",
"     \"Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, women with laboratory criteria for aPL and a prior history of arterial or venous thrombosis are at high risk of recurrence and are generally on lifelong anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , which should be resumed postpartum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT FAILURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pregnancy loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women have adverse pregnancy outcomes despite use of the treatments described above. In these cases, consideration of other, less well studied, and potentially more morbid, therapies is an option during the next pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous gamma globulin (IVIG) (0.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day for five days each month during the next attempted pregnancy) is one alternative treatment that has been proposed; however, the efficacy of this approach has not been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/21,54-56\">",
"     21,54-56",
"    </a>",
"    ]. Use of IVIG should probably be confined to research studies.",
"   </p>",
"   <p>",
"    The following are summaries of some selected clinical trials of IVIG for prevention of pregnancy loss:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter, randomized pilot study including 16 women with well-documented APS reported that treatment with IVIG did not significantly improve the rates of preeclampsia, IUGR, nonreassuring fetal heart rate patterns, and neonatal intensive care unit admission, or the gestational age at delivery and birth weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/56\">",
"       56",
"      </a>",
"      ]. However, it is unclear whether this lack of benefit extends to those who fail initial treatment with low dose ASA plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Among women with prior spontaneous abortions, no difference in live-birth rates was found when 53 women with APS who received IVIG at one obstetrical center were compared to another group of 29 women contemporaneously treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and low dose ASA at another center (live birth rate 78 and 76 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/57\">",
"       57",
"      </a>",
"      ]. However, a smaller percentage of women in the IVIG treated group developed hypertension or maternal diabetes (5 versus 14 percent).",
"     </li>",
"     <li>",
"      A study including 40 women compared the efficacy of the combination of low dose ASA and LMWH to use of IVIG for the prevention of recurrent fetal loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/21\">",
"       21",
"      </a>",
"      ]. Each group received either LMWH (5700",
"      <span class=\"nowrap\">",
"       units/day",
"      </span>",
"      subcutaneously) and ASA (75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or IVIG (400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously for two days, followed by 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      monthly). The percentage of live births was greater in the LMWH and low dose ASA group than the IVIG group (84 percent and 57 percent, respectively). There were no serious adverse effects of either therapy and no thromboembolic events in either group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis has been used to treat pregnant women with documented APS when first line therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) failed to prevent pregnancy loss. Data are limited to case reports and a small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Randomized trials and larger series are needed to determine whether these therapies have a role in clinical practice.",
"   </p>",
"   <p>",
"    One report performed repeated exchanges of approximately three to four treatments per week starting at the 14th week of pregnancy and continuing until cesarean delivery at 34 weeks; another performed a total of six exchanges beginning at the 24th week followed by cesarean delivery at week 29. Both documented a reduction in antibody titers following apheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. A third report described a woman with a history of thrombotic events, a previous pregnancy loss at the 11th week of gestation, lupus anticoagulant activity, and high titers of IgG anticardiolipin antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/60\">",
"     60",
"    </a>",
"    ]. Weekly plasma exchanges were performed, but the patient delivered in the 26th week due to fetal growth restriction and oligohydramnios. The female infant weighed 730 g and survived.",
"   </p>",
"   <p>",
"    The largest series included 18 pregnant women who received both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and plasmapheresis for three sessions per week until lupus anticoagulant activity was suppressed and the IgG anticardiolipin titer decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/61\">",
"     61",
"    </a>",
"    ]. The live birth rate was 100 percent; pregnancy complications included preterm delivery (22 percent), oligohydramnios and fetal distress (16 percent), intrauterine growth restriction (11 percent), mild preeclampsia (5 percent), and thrombocytopenia (5 percent). There were no perinatal deaths, thrombotic events, or lupus flares.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hydroxychloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimalarial drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    appears to reverse platelet activation induced by human IgG aPL and reverse thrombogenic properties of aPL in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], and also appears to depress aPL levels in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/64\">",
"     64",
"    </a>",
"    ]. These effects might be beneficial in women with APS-related recurrent pregnancy loss, but no data are available. Case series have not described teratogenicity with use of hydroxychloroquine in pregnant women with SLE and miscarriage rates have been similar in treated and untreated women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Hydroxychloroquine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Interleukin -3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in an animal model of APS have shown a dramatic reduction in fetal loss by the administration of interleukin-3, which may act by increasing plasminogen activator activity and by directly stimulating trophoblast growth and hormone production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/2,65\">",
"     2,65",
"    </a>",
"    ]. The applicability of this observation to humans is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Venous thromboembolism during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If venous thrombosis occurs despite prophylactic measures, the diagnostic and therapeutic approach is essentially the same as that for newly diagnosed idiopathic venous thrombosis in any pregnant woman. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, if venous thromboembolism develops during pregnancy despite therapeutic anticoagulation, it may be necessary to use an inferior vena cava filter in conjunction with anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREGNANCY MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with APS should be counseled regarding the medical and obstetrical consequences of the disorder prior to pregnancy. There are no high quality data on which to base recommendations for maternal or fetal surveillance. During pregnancy, experts suggest close maternal and fetal monitoring to allow timely intervention in the event of maternal or pregnancy complications. In addition to routine prenatal care, surveillance includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum creatinine concentration, urine protein-to-creatinine ratio, and assessment of serum",
"      <span class=\"nowrap\">",
"       AST/ALT",
"      </span>",
"      at the beginning of the pregnancy to determine baseline renal and hepatic function.",
"     </li>",
"     <li>",
"      Education regarding the signs and symptoms of thromboembolic disease and preeclampsia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"       \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Early sonography to establish a definitive estimated date of delivery, followed by serial sonograms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/37\">",
"       37",
"      </a>",
"      ] every three to four weeks in the late second and the third trimesters to evaluate fetal growth and amniotic fluid volume. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22906?source=see_link\">",
"       \"Diagnosis of fetal growth restriction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Umbilical artery Doppler flow analyses if fetal growth restriction is diagnosed. Monitoring the growth restricted fetus with this technique reduces perinatal mortality. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"       \"Fetal growth restriction: Evaluation and management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10728?source=see_link\">",
"       \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antepartum fetal assessment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=see_link\">",
"       \"Antepartum fetal heart rate assessment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11928?source=see_link\">",
"       \"The fetal biophysical profile\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Labor and delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who are being treated with anticoagulation, we suggest scheduled delivery at 39 weeks to minimize anticoagulant exposure and to decrease the risk that an anticoagulant dose will be given proximate to active labor. Management of anticoagulation proximate to labor and delivery is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3351?source=see_link&amp;anchor=H8#H8\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\", section on 'Labor and delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for pregnancy outcome in those with APS depends upon the patient's prior medical and obstetrical history and whether they have been treated.",
"   </p>",
"   <p>",
"    In women with a prior history of two or more fetal losses, there is a 70 to 80 percent live birth rate for patients treated with some combination of the above modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/13,14,18,66-69\">",
"     13,14,18,66-69",
"    </a>",
"    ]. However, even among patients with live births, there is an increased risk of complications relating to the pregnancy (preterm birth, preeclampsia, growth restriction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term effects of maternal APS on offspring are not clear. In one study of 55 infants born to women with aPL, no malformations, thromboses, neurodevelopmental delay, or significant problems were observed during the first five years of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/71\">",
"     71",
"    </a>",
"    ]. However, in another study, 4 of 15 children born to aPL positive women had abnormal scores on reading and writing tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/0/44041/abstract/72\">",
"     72",
"    </a>",
"    ]. Further investigation of the long-term outcome of offspring is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with the antiphospholipid syndrome (APS) are at increased risk for maternal thrombosis and for late fetal loss, early and severe preeclampsia, growth restriction, and, possibly, recurrent early pregnancy loss. The management of these women is controversial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with antiphospholipid antibodies (aPL) and prior thrombosis but no pregnancy complications, we suggest antepartum and postpartum thromboprophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest addition of low dose ASA for women who also have a history of APS-defining pregnancy complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'APS based on aCL and prior thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with aPL and no prior thrombosis and no pregnancy complications, acceptable options include close clinical surveillance, antepartum prophylactic unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin, or antepartum low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (ASA). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'aCL or lupus anticoagulant alone without clinical criteria for APS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with aPL and one or more fetal losses at or after 10 weeks of gestation, we suggest combined therapy with low dose ASA and prophylactic low molecular weight heparins (LMWH) during pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'One or more late fetal losses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For selected women with aPL and a history of multiple embryonic losses in whom other etiologies have been excluded, we suggest low dose ASA and prophylactic LMWH therapy during pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Recurrent embryonic losses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with aPL and a history of early and severe preeclampsia or fetal growth restriction necessitating delivery before 34 weeks of gestation, we suggest low dose ASA therapy in the second and third trimesters (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We may prescribe",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or LMWH with low dose ASA in cases of ASA failure or when placental examination shows prior extensive thrombosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Early and severe preeclampsia or growth restriction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticoagulation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin should be initiated in the first trimester, after confirmation of intrauterine pregnancy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recommendations for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or LMWH antepartum, we suggest continuing anticoagulation for six weeks after delivery. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Postpartum women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/1\">",
"      Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/2\">",
"      Fishman P, Falach-Vaknin E, Sredni B, et al. Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. J Rheumatol 1995; 22:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/3\">",
"      Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/4\">",
"      Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/5\">",
"      Hirsh J, Guyatt G, Albers GW, et al. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:71S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/6\">",
"      Ermel LD, Marshburn PB, Kutteh WH. Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL). Am J Reprod Immunol 1995; 33:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/7\">",
"      Franklin RD, Kutteh WH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol 2003; 101:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/8\">",
"      Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/9\">",
"      Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/10\">",
"      Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/11\">",
"      Adams M. Novel considerations in the pathogenesis of the antiphospholipid syndrome: involvement of the tissue factor pathway of blood coagulation. Semin Thromb Hemost 2008; 34:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/12\">",
"      Girardi G, Mackman N. Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule. Lupus 2008; 17:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/13\">",
"      Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/14\">",
"      Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/15\">",
"      Lockshin MD. Answers to the antiphospholipid-antibody syndrome? N Engl J Med 1995; 332:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/16\">",
"      Rosove MH, Tabsh K, Wasserstrum N, et al. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 1990; 75:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/17\">",
"      Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/18\">",
"      Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/19\">",
"      Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996; 35:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/20\">",
"      Backos M, Rai R, Baxter N, et al. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 1999; 106:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/21\">",
"      Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003; 48:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/22\">",
"      Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/23\">",
"      Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010; 115:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/24\">",
"      Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010; 49:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/25\">",
"      Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004; 26:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/26\">",
"      Gris JC, Balducchi JP, Qu&eacute;r&eacute; I, et al. Enoxaparin sodium improves pregnancy outcome in aspirin-resistant antiphospholipid/antiprotein antibody syndromes. Thromb Haemost 2002; 87:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/27\">",
"      Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/28\">",
"      Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/29\">",
"      Silver RK, MacGregor SN, Sholl JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993; 169:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/30\">",
"      Bramham K, Thomas M, Nelson-Piercy C, et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011; 117:6948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/31\">",
"      Harris EN, Pierangeli SS. Antiphospholipid antibodies and the antiphospholipid syndrome. Springer Semin Immunopathol 1994; 16:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/32\">",
"      Tincani A, Branch W, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003; 12:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/33\">",
"      Galli M, Barbui T. Antiphospholipid antibodies and pregnancy. Best Pract Res Clin Haematol 2003; 16:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/34\">",
"      Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med 2003; 349:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/35\">",
"      Crowther MA, Wisloff F. Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thromb Res 2005; 115:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/36\">",
"      Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnancy--a systematic review of randomized therapeutic trials. Thromb Res 2004; 114:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/37\">",
"      Committee on Practice Bulletins&mdash;Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: Antiphospholipid syndrome. Obstet Gynecol 2012; 120:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/38\">",
"      Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/39\">",
"      Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/40\">",
"      Kutteh WH, Rote NS, Silver R. Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. Am J Reprod Immunol 1999; 41:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/41\">",
"      Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/42\">",
"      Lockwood CJ, Romero R, Feinberg RF, et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/43\">",
"      Del Ross T, Ruffatti A, Visentin MS, et al. Treatment of 139 Pregnancies in Antiphospholipid-positive Women Not Fulfilling Criteria for Antiphospholipid Syndrome: A Retrospective Study. J Rheumatol 2013; 40:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/44\">",
"      Denis AL, Guido M, Adler RD, et al. Antiphospholipid antibodies and pregnancy rates and outcome in in vitro fertilization patients. Fertil Steril 1997; 67:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/45\">",
"      Chilcott IT, Margara R, Cohen H, et al. Pregnancy outcome is not affected by antiphospholipid antibody status in women referred for in vitro fertilization. Fertil Steril 2000; 73:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/46\">",
"      Steinvil A, Raz R, Berliner S, et al. Association of common thrombophilias and antiphospholipid antibodies with success rate of in vitro fertilisation. Thromb Haemost 2012; 108:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/47\">",
"      Hornstein MD, Davis OK, Massey JB, et al. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis. Fertil Steril 2000; 73:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/48\">",
"      Practice Committee of American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. Fertil Steril 2008; 90:S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/49\">",
"      American Society for Reproductive Medicine 56th annual meeting. October 21-26, 2000. San Diego, California, USA. Abstracts. Fertil Steril 2000; 74:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/50\">",
"      Hornstein MD. Antiphospholipid antibodies in patients undergoing IVF: the data do not support testing. Fertil Steril 2000; 74:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/51\">",
"      Clark CA, Spitzer KA, Crowther MA, et al. Incidence of postpartum thrombosis and preterm delivery in women with antiphospholipid antibodies and recurrent pregnancy loss. J Rheumatol 2007; 34:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/52\">",
"      Gris JC, Bouvier S, Molinari N, et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119:2624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/53\">",
"      Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/54\">",
"      Scott JR, Branch DW, Kochenour NK, Ward K. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization. Am J Obstet Gynecol 1988; 159:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/55\">",
"      Spinnato JA, Clark AL, Pierangeli SS, Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 1995; 172:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/56\">",
"      Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000; 182:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/57\">",
"      Vaquero E, Lazzarin N, Valensise H, et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. Am J Reprod Immunol 2001; 45:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/58\">",
"      Frampton G, Cameron JS, Thom M, et al. Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. Lancet 1987; 2:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/59\">",
"      Fulcher D, Stewart G, Exner T, et al. Plasma exchange and the anticardiolipin syndrome in pregnancy. Lancet 1989; 2:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/60\">",
"      Bortolati M, Marson P, Chiarelli S, et al. Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome. Ther Apher Dial 2009; 13:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/61\">",
"      El-Haieg DO, Zanati MF, El-Foual FM. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet 2007; 99:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/62\">",
"      Espinola RG, Pierangeli SS, Gharavi AE, et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/63\">",
"      Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96:4380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/64\">",
"      Toubi E, Kessel A, Rosner I, et al. Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE. Lupus 2003; 12:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/65\">",
"      Fishman P, Falach-Vaknine E, Zigelman R, et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993; 91:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/66\">",
"      Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/67\">",
"      Farquharson RG, Pearson JF, John L. Lupus anticoagulant and pregnancy management. Lancet 1984; 2:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/68\">",
"      Joffe AM, Hoskins CF, Ghitter-Mannes SC, Mant MJ. Anticoagulant therapy for prevention of spontaneous abortion in a patient with a lupus anticoagulant. Am J Hematol 1988; 29:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/69\">",
"      Jungers P, Liote F, Dautzenberg MD, et al. Lupus anticoagulant and thrombosis in systemic lupus erythematosus. Lancet 1984; 1:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/70\">",
"      Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/71\">",
"      Ruffatti A, Dalla Barba B, Del Ross T, et al. Outcome of fifty-five newborns of antiphospholipid antibody-positive mothers treated with calcium heparin during pregnancy. Clin Exp Rheumatol 1998; 16:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/0/44041/abstract/72\">",
"      Tincani A, Rebaioli CB, Andreoli L, et al. Neonatal effects of maternal antiphospholipid syndrome. Curr Rheumatol Rep 2009; 11:70.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6816 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44041=[""].join("\n");
var outline_f43_0_44041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF INITIAL TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heparin/heparin with aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Unfractionated versus LMW heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44846195\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RECOMMENDATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      APS based on aCL and prior thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20154608\">",
"      APS based on aCL and pregnancy-related clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - One or more late fetal losses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Recurrent embryonic losses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Early and severe preeclampsia or growth restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      aCL or lupus anticoagulant alone without clinical criteria for APS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hydroxychloroquine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Interleukin -3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Venous thromboembolism during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREGNANCY MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6816\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6816|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/8/26752\" title=\"table 1\">",
"      CDC modifications to WHO eligibility for contraceptive use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/6/8298?source=related_link\">",
"      Definition and etiology of recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16646?source=related_link\">",
"      Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11928?source=related_link\">",
"      The fetal biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_0_44042="Scleroderma glomerulus light";
var content_f43_0_44042=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70213%7ENEPH%2F54840%7ENEPH%2F69687%7ENEPH%2F78330%7ENEPH%2F75317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70213%7ENEPH%2F54840%7ENEPH%2F69687%7ENEPH%2F78330%7ENEPH%2F75317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopy of glomerulus in scleroderma renal crisis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph showing fibrinoid necrosis in the preglomerular afferent arteriole (arrow) in scleroderma renal crisis. The normal muscle layer of the media has been replaced by the fibrinoid material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopy showing thrombotic microangiopathy with subintimal fibrin deposition in an interlobular artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subintimal fibrin deposition without inflammation (arrow) in an interlobular artery as can be seen acutely in any of the forms of the hemolytic-uremic syndrome, including scleroderma. The marked narrowing of the vascular lumen will diminish distal perfusion, potentially leading to tissue necrosis if there is near total or total occlusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopy showing thrombotic microangiopathy with mucoid intimal thickening of a muscular renal artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mucoid intimal thickening of muscular renal arteries (arrows) as an early healing response to previous fibrinoid injury in any of the forms of the hemolytic-uremic syndrome, including scleroderma and malignant hypertension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopy showing thrombotic microangiopathy with onion-skin thickening of a muscular renal artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Concentric onion-skin thickening of a muscular renal artery, leading to complete obliteration of the vascular lumen, during the later healing phase of previous fibrinoid injury in any of the forms of the hemolytic-uremic syndrome, including scleroderma and malignant hypertension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence microscopy showing fibrin deposition in thrombotic microangiopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in the hemolytic-uremic syndrome shows fibrin deposition (bright yellow areas) in branches of a muscular renal artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44042=[""].join("\n");
var outline_f43_0_44042=null;
var title_f43_0_44043="Saw palmetto quality criteria";
var content_f43_0_44043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of Saw palmetto products and brands meeting specified quality criteria*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Product name (manufacturer or distributor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doctor's Best Saw Palmetto Extract (Doctor's Best)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CVS Pharmacy Saw Palmetto (CVS Corporation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GNC Herbal Plus Standardized Saw Palmetto (General Nutrition Corporation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solgar Saw Palmetto Berry Extract (Solgar Vitamin and Herb)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        <p>",
"         Examples of products passing testing. Full report at www.consumerlabs.com.",
"        </p>",
"        <p>",
"         * To pass testing, products had to meet all of the following criteria:",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. A labeled daily dosage that would provide daily dosage of at least 320 mg of saw palmetto berry extract or 1 to 2 grams of saw palmetto berry powder and standardized to include 85 to 95 percenttotal fatty acids and 0.2 percent total sterols.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Products must contain 100 to 150 percent of the claimed amounts of total fatty acids and total sterols.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Individual fatty acids must be present as follows: caproicacid (0.3 to 0.8 percent), caprylic acid (1.0 to 3.0 percent), capricacid (1.0 to 3.0 percent), lauric acid (25.0 to 32.0 percent), myristicacid (10.0 to 15.0 percent), palmitic acid (7.0 to 11.0 percent), stearic acid (1.0 to 2.0 percent), oleic acid (26.0 to 35.0 percent), cislinoleic acid (3.0 to 5.0 percent), lineolic acid (0.5 to 1.5 percent).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Individual sterols must be present as follows: campesterol (0.01 to 0.1 percent), stigmasterol (0.01 to 0.1 percent), and beta-sitosterol (0.1 to 0.4 percent).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. USP parameters for disintegration of vitamin supplements.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44043=[""].join("\n");
var outline_f43_0_44043=null;
var title_f43_0_44044="Weaning predictors";
var content_f43_0_44044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Weaning predictors",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Measurements of oxygenation and gas exchange",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /PAO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alveolar-arterial (A-a) oxygen gradient",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dead space (V",
"       <sub>",
"        D",
"       </sub>",
"       /V",
"       <sub>",
"        T",
"       </sub>",
"       )",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Simple measurements of respiratory system load and respiratory muscle capacity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Negative inspiratory force (NIF) or maximal inspiratory pressure (MIP)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory system compliance (dynamic, static)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory system resistance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Total minute ventilation*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vital capacity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory frequency*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tidal volume*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Integrative indices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Frequency-tidal volume ratio, f/V",
"       <sub>",
"        T",
"       </sub>",
"       , or rapid shallow breathing index (RSBI)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CROP index (dynamic",
"       <strong>",
"        C",
"       </strong>",
"       ompliance,",
"       <strong>",
"        R",
"       </strong>",
"       espiratory rate,",
"       <strong>",
"        O",
"       </strong>",
"       xygenation, maximal inspiratory",
"       <strong>",
"        P",
"       </strong>",
"       ressure)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Integrative Weaning Index (IWI)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inspiratory Effort Quotient (IEQ)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Complex measurements (may require special equipment)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Airway occlusion pressure measured at 100 msec (P0.1)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       P0.1/MIP*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Esophageal pressure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oxygen cost of breathing (O2COB)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mechanical work of breathing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pdi/Pdimax",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tension-time index",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastric intramucosal pH or P",
"       <sub>",
"        g",
"       </sub>",
"       CO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial oxygen tension; PAO",
"     <sub>",
"      2",
"     </sub>",
"     : alveolar oxygen; FiO",
"     <sub>",
"      2",
"     </sub>",
"     : fraction of inspired oxygen; Pdi: diaphragmatic pressure; P",
"     <sub>",
"      g",
"     </sub>",
"     CO",
"     <sub>",
"      2",
"     </sub>",
"     : gastric carbon dioxide tension.",
"     <br>",
"      * Predictors found to be most accurate in a systematic review.",
"      <sup>",
"       [2]",
"      </sup>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     1. Adapted from: Epstein, SK. Weaning from ventilatory support. In: Textbook of Pulmonary Diseases, 7th Edition, Crapo, JD, Glassroth, J, Karlinsky, J, King, TE (eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2003. p. 1089.",
"     <br>",
"      2. Meade, M, Guyatt, G, Cook, D, et al. Predicting success in weaning from mechanical ventilation. Chest 2001; 120:400S.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44044=[""].join("\n");
var outline_f43_0_44044=null;
var title_f43_0_44045="PaO2 div FiO2 proning schedule";
var content_f43_0_44045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Course of PaO",
"    <sub>",
"     2",
"    </sub>",
"    /FiO",
"    <sub>",
"     2",
"    </sub>",
"    during four consecutive 24-hour periods of prone positioning",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 297px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In each period, patients were prone (p) 20 hours and supine (s) 4 hours. A benefit from prone positioning was observed during repeated transitions from supine to prone position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fridrich, P, Krafft, P, Hochleuthner, H, et al., Anesth Analg 1996; 83:1206.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44045=[""].join("\n");
var outline_f43_0_44045=null;
var title_f43_0_44046="Perivascular sheathing retina";
var content_f43_0_44046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perivascular sheathing of retinal vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Funduscopic examination shows perivascular sheathing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44046=[""].join("\n");
var outline_f43_0_44046=null;
var title_f43_0_44047="Elbow joint PI";
var content_f43_0_44047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elbow joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The elbow is made up of 3 bones (the radius, ulna, and humerus).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_0_44047=[""].join("\n");
var outline_f43_0_44047=null;
